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Introduction {#s1}
============

Certain risky health behaviors, such as tobacco use and significant alcohol consumption, are known to affect disease risk by impairing the immune response. Studies have documented impaired mucosal immunity among smokers compared with nonsmokers [@pone.0102154-Edwards1] and negative cellular and innate immune system effects among excessive alcohol consumers [@pone.0102154-Cook1]--[@pone.0102154-Roseman1], providing a basis for a differential vaccine effectiveness of the available influenza vaccines that use different delivery methods. Since smoking and alcohol use are associated with a higher risk of respiratory infections including influenza, defining optimal vaccine strategies among these groups is important for both patient care and public health strategies [@pone.0102154-Meyerholz1]--[@pone.0102154-Finklea1].

Vaccination against influenza virus has been a common practice since the vaccine\'s development in 1945 [@pone.0102154-Stanley1], and is the single most effective prevention strategy [@pone.0102154-Jefferson1]--[@pone.0102154-Fiore1]. Since it is expected that the majority of individuals worldwide will remain susceptible to one or more circulating influenza strains at any given time, continued understanding of optimal vaccine practices is essential. Two of the influenza vaccine types currently licensed in the United States include the trivalent inactivated influenza vaccine (TIV), an older formulation, and live, attenuated influenza vaccine (LAIV), licensed since 2003. TIV is prepared by killing influenza viruses and isolating subvirion or purified surface antigens to create "split" or subunit vaccines [@pone.0102154-Cox1], while LAIV comprises attenuated live viruses. Vaccine antigens contained in LAIV and TIV are presented to an individual\'s immune system through markedly different routes: TIV is injected, causing rapid distribution into the bloodstream and induction of a humoral response, while LAIV virions are delivered to the nasopharyngeal epithelial cells where they appear to induce both humoral (mucosal IgA antibody) and cell-mediated immune responses [@pone.0102154-Cox2].

Because various immune mechanisms are involved to differing degrees between the two vaccine methods, the immune response induced by each could differ among individuals with altered immunity. In addition to smoking and alcohol use, intense exercise may alter immunity through various mechanisms including transient reduced salivary IgA levels [@pone.0102154-Nieman1]--[@pone.0102154-Eskola1], providing a basis for a potential differential vaccine response to LAIV versus TIV. Likewise, though its immune effects are not well established, a sedentary lifestyle may result in adverse health consequences, while exercise has been shown to boost immunity [@pone.0102154-McGinnis1]--[@pone.0102154-Venjatraman1]. Hence, differential vaccine responses by exercise level are plausible.

Given the high prevalence of adverse health-related behaviors in the general population [@pone.0102154-U1], a statistical difference in vaccine effectiveness between LAIV and TIV in these risk groups would likely correspond to a significant influenza disease burden that could be eliminated with tailored vaccine protocols. The risk of influenza-like illness (ILI) by vaccine type received among smokers, those with a potential alcohol problem, and those reporting varying levels of exercise was evaluated in this study.

Methods {#s2}
=======

Study Population and Data Sources {#s2a}
---------------------------------

A retrospective cohort study was conducted during 2012--2013 among US military members who completed a health survey for a large prospective Department of Defense study (Millennium Cohort Study) [@pone.0102154-Ryan1] within 2 years of influenza vaccination. Subjects were active-duty members stationed in the United States at the beginning of the influenza season who received influenza vaccination during the 2006/2007 and/or 2008/2009 seasons. These seasons were chosen because vaccine strains were well matched to circulating influenza strains, according to surveillance data published by the Centers for Disease Control and Prevention (CDC) [@pone.0102154-Centers1]--[@pone.0102154-Centers3]. Although 66% of influenza A (H1N1) viruses were found to be similar to the vaccine strain, the 2007/2008 influenza season was excluded as 77% of influenza A (H3N2) and 98% of B viruses were poorly matched [@pone.0102154-Centers4]. All participants were aged 18--49 years at the time of vaccination since LAIV use is limited to adults ≤49 years of age. Exclusion criteria included a diagnosis of asthma, chronic bronchitis, emphysema, history of shortness of breath, diabetes mellitus, HIV infection, or pregnancy, since LAIV use may have been contraindicated and these conditions may result in suboptimal vaccine responses. Data on preexisting medical diagnoses were obtained from the Millennium Cohort survey and medical records. Additionally, pharmacy records (Pharmacy Data Transaction Service) were used to exclude subjects receiving medications for diabetes mellitus or HIV. Non--active duty military personnel, personnel deployed at the time of study, and members stationed on ships or overseas were excluded because these groups may be exposed to influenza strains not covered in the vaccine and outcomes of interest may not be captured in existing databases. Additionally, military recruits were excluded given their unique risks for respiratory illnesses [@pone.0102154-Dudding1]--[@pone.0102154-Russell1].

The type and date of influenza vaccinations were obtained from military records maintained by the Defense Manpower Data Center (DMDC). Annual influenza vaccination is mandatory for active-duty members, though the type of vaccine (TIV or LAIV) is often based on available supply. The study was approved by the Institutional Review Board at the Naval Health Research Center (protocol NHRC.2010.0027), in accordance with 32 CFR §219. l 16(d) and classified as minimal risk. The IRB waived the requirement to obtain informed consent because it is impractical with numerous record holders that are geographically widely-dispersed, and the decision to waive informed consent will not adversely affect the rights and welfare of the record holders of this study population.

Study Outcome {#s2b}
-------------

The outcome of interest was ILI, chosen because laboratory testing for influenza virus is not commonly employed and because ILI has both medical and occupational significance. The diagnosis of ILI was determined by review of *International Classification of Diseases, 9th Revision* (ICD-9) codes in the Military Health System Data Repository, which contains all outpatient and inpatient encounters from military treatment facilities and care provided by TRICARE network providers. An ILI case was defined by the presence of specific ICD-9 codes ([Table 1](#pone-0102154-t001){ref-type="table"}) shown in previous studies to be related to culture-confirmed influenza in military service members [@pone.0102154-Eick1], [@pone.0102154-MarsdenHaug1]. Independent of the presence of these ICD-9 codes, anti-influenza medication dispensing (i.e., oseltamivir, zanamivir, amantadine, or rimantadine) documented in pharmacy records was also considered to represent a case.

10.1371/journal.pone.0102154.t001

###### ICD-9 Codes Used To Identify Influenza-like Illness.

![](pone.0102154.t001){#pone-0102154-t001-1}

  ICD-9 Code                       Description
  ------------ ---------------------------------------------------
  079.99                      Viral infection, NOS
  382.9                         Otitis media, NOS
  460.0                      Nasopharyngitis, acute
  461.9                   Acute sinusitis, unspecified
  465.8         Upper respiratory infection, other multiple sites
  465.9              Upper respiratory infection, acute NOS
  466.0                Bronchitis and bronchiolitis, acute
  486.0                  Pneumonia, organism unspecified
  487.0                     Influenza with pneumonia
  487.1          Influenza with other respiratory manifestations
  487.8                Influenza with other manifestations
  490.0           Bronchitis, not specified as acute or chronic
  780.6                               Fever
  786.2                               Cough

Outcomes were captured beginning September 1 of each season, and only the first ILI event per subject in each season was considered in the analyses. Subjects with an event during the current influenza season occurring prior to 14 days post vaccination were excluded from analyses to ensure that only vaccinated individuals with adequate time for development of an immune response and no recent influenza infection were studied. Subjects were followed from the time of influenza vaccination (administered September 1--November 30 of each season) until the end of the influenza season (May 19, 2007, and March 28, 2009; the latter season truncated given the emergence of the pandemic H1N1 strain) for occurrence of an ILI outcome, or censoring event [@pone.0102154-Centers3], [@pone.0102154-Dawood1]. Individuals were right-censored if they deployed by land or aboard ship or transferred outside the continental United States. Subjects could contribute to both influenza seasons if they received vaccine and met the inclusion/exclusion criteria during each season.

Exposures of Interest {#s2c}
---------------------

Three specific exposures of interest were evaluated: recent smoking history, potential alcohol problem, and exercise level. Exposure data were obtained from self-reported survey information from the Millennium Cohort Study. Recent smoking history was defined as reporting both ≥100 cigarettes in a lifetime and cigarette use within the last year. Potential alcohol problems were defined as an affirmative answer to 1 or more of the 5 alcohol questions on the Patient Health Questionnaire [@pone.0102154-Jacobson1], which represents a positive screen for alcohol abuse [@pone.0102154-Spitzer1]. Exercise was categorized based on the current CDC physical activity recommendations [@pone.0102154-Centers5]: the number of days exercised per week at a moderate level multiplied by time (in minutes) plus twice the number of days per week of vigorous exercise multiplied by time. If the result was \<150 minutes then the exercise level was minimal, and if 6--7 days per week of vigorous activity was reported then the level was high; otherwise, the classification was moderate. Those with missing exercise activity data were denoted as unknown.

Covariates {#s2d}
----------

Information on sociodemographic and military-related characteristics were obtained from DMDC and included age, sex, self-reported race/ethnicity, marital status, service branch, military pay grade (enlisted, officer), duty station (coded into four geographic areas), occupation, and deployment history.

Statistical Analyses {#s2e}
--------------------

Descriptive statistics are presented as numbers (percentages) for categorical variables and medians (interquartile range, IQR) for continuous variables. The univariable associations between the covariates and vaccine type were assessed using logistic regression (for categorical variables) and the Wilcoxon rank-sum test for age (continuous). Crude incidence rates of ILI per 1000 persons per season were compared between the LAIV- and TIV-immunized groups. Cox proportional hazard modeling was used to evaluate the unadjusted and adjusted risk (time to event) for ILI by vaccine type (LAIV vs TIV) as well as other covariates of interest (sociodemographic, military, geographic, and behavioral factors). To test the hypothesis that relative vaccine effectiveness is differential by specific health behavior (smoking, alcohol, and exercise level), an interaction term with vaccine type was added to the model for each behavior. In addition, interactions were evaluated between vaccine type and 3 covariates: sex, service branch, and influenza season. In order to adjust for the potential effects of individuals contributing to multiple seasons, a robust variance estimator was used. To account for individuals receiving the vaccination at different times in relation to the influenza season, a left-truncated model was developed starting survival time at September 1 of the influenza season and truncating on date of vaccination plus 14 days. Follow-up time was measured from September 1 of each influenza season until an outcome was observed or the censor date. A final multivariable model was derived using a backward, stepwise approach and was adjusted for covariates significantly associated with the outcome (*p*\<0.05) or that confounded the relationship between vaccine type and ILI by ≥10%. Results of the Cox models are presented as hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical analyses were performed using SAS software, version 9.3 (SAS Institute, Inc., Cary, NC).

Results {#s3}
=======

Overall, 28,929 vaccination events were studied during the 2 influenza seasons (2006/2007 and 2008/2009), including 22,734 (79%) LAIV and 6195 (21%) TIV administrations. The median age of the cohort was 27 years (IQR, 23--34), 73% were white, and 73% male. Regarding health-related behaviors, 27.5% subjects reported a recent smoking history and 7.7% a potential alcohol problem. Exercise levels were distributed as follows: 10.5% minimal, 70.3% moderate, 4.4% high, and 14.7% unknown ([Table 2](#pone-0102154-t002){ref-type="table"}).

10.1371/journal.pone.0102154.t002

###### Population Characteristics[a](#nt102){ref-type="table-fn"} Among US Service Members, 18--49 Years of Age, During Two Influenza Seasons (2006/2007, 2008/2009).
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                                Total Study     2006/2007     2008/2009    Combined Seasons                              
  --------------------------- --------------- ------------- ------------- ------------------ ------------- ------------- ---------------
  Number                          28,929          2905         10,316            3290           12,418         6195          22,734
  ILI event                     3936 (13.6)    383 (13.2)    1477 (14.3)      404 (12.3)      1672 (13.5)   787 (12.7)     3149 (13.9)
  Recent smoking history        7955 (27.5)    776 (26.7)    2814 (27.3)      941 (28.6)      3424 (27.6)   1717 (27.7)    6238 (27.4)
  Potential alcohol problem     2221 (7.7)     292 (10.1)     760 (7.4)       274 (8.3)        895 (7.2)     566 (9.1)     1655 (7.3)
  Exercise level                                                                                                         
  Minimal                       3039 (10.5)    345 (11.9)    1062 (10.3)      360 (10.9)      1272 (10.2)   705 (11.4)     2334 (10.3)
  Moderate                     20,345 (70.3)   2021 (69.6)   7243 (70.2)     2292 (69.7)      8789 (70.8)   4313 (69.6)   16,032 (70.5)
  High                          1283 (4.4)      139 (4.8)     461 (4.5)       137 (4.2)        546 (4.4)     276 (4.5)     1007 (4.4)
  Unknown                       4262 (14.7)    400 (13.8)    1550 (15.0)      501 (15.2)      1811 (14.6)   901 (14.5)     3361 (14.8)
  Age, years                    27 (23--34)    25 (22--32)   25 (22--33)     28 (24--35)      27 (24--35)   27 (23--34)    27 (23--34)
  Sex                                                                                                                    
  Male                         21,003 (72.6)   2046 (70.4)   7537 (73.1)     2241 (68.1)      9179 (73.9)   4287 (69.2)   16,716 (73.5)
  Female                        7926 (27.4)    859 (29.6)    2779 (26.9)     1049 (31.9)      3239 (26.1)   1908 (30.8)    6018 (26.5)
  Race/ethnicity                                                                                                         
  White/non-Hispanic           21,090 (72.9)   2195 (75.6)   7520 (72.9)     2345 (71.3)      9030 (72.7)   4540 (73.3)   16,550 (72.8)
  Black/non-Hispanic            3620 (12.5)     286 (9.8)    1305 (12.7)      446 (13.6)      1583 (12.7)   732 (11.8)     2888 (12.7)
  Hispanic                      2077 (7.2)      206 (7.1)     714 (6.9)       261 (7.9)        896 (7.2)     467 (7.5)     1610 (7.1)
  Other/unknown                 2142 (7.4)      218 (7.5)     777 (7.5)       238 (7.2)        909 (7.3)     456 (7.4)     1686 (7.4)
  Marital status                                                                                                         
  Married                      17,857 (61.7)   1605 (55.2)   5847 (56.7)     2233 (67.9)      8172 (65.8)   3838 (62.0)   14,019 (61.7)
  Other                        11,072 (38.3    1300 (44.8)   4469 (43.3)     1057 (32.1)      4246 (34.2)   2357 (38.1)    8715 (38.3)
  Service branch                                                                                                         
  Air Force                    14,291 (49.4)   1168 (40.2)   5469 (53.0)     1215 (36.9)      6439 (51.9)   2383 (38.5)   11,908 (52.4)
  Army                          9405 (32.5)    651 (22.4)    3639 (35.3)      923 (28.1)      4192 (33.8)   1574 (25.4)    7831 (34.5)
  Marine Corps                  2974 (10.3)    774 (26.6)     679 (6.6)       651 (19.8)       870 (7.0)    1425 (23.0)    1549 (6.8)
  Navy                          2259 (7.8)     312 (10.7)     529 (5.1)       501 (15.2)       917 (7.4)    813 (13.1)     1446 (6.4)
  Rank                                                                                                                   
  Enlisted                     21,931 (75.8)   2117 (72.9)   7914 (76.7)     2421 (73.6)      9479 (76.3)   4538 (73.3)   17,393 (76.5)
  Officer                       6998 (24.2)    788 (27.1)    2402 (23.3)      869 (26.4)      2939 (23.7)   1657 (26.8)    5341 (23.5)
  Occupation                                                                                                             
  Combat                        5231 (18.1)    478 (16.5)    1821 (17.7)      542 (16.5)      2390 (19.2)   1020 (16.5)    4211 (18.5)
  Health care                   4280 (14.8)    592 (20.4)    1449 (14.0)      724 (22.0)      1515 (12.2)   1316 (21.2)    2964 (13.0)
  Other                        19,418 (67.1)   1835 (63.2)   7046 (68.3)     2024 (61.5)      8513 (68.6)   3859 (62.3)   15,559 (68.4)
  US geographic area                                                                                                     
  Southwest                     8746 (30.2)    1101 (37.9)   2997 (29.1)     1348 (41.0)      3300 (26.6)   2449 (39.5)    6297 (27.7)
  Southeast                     8992 (31.1)    966 (33.3)    3322 (32.2)      954 (29.0)      3750 (30.2)   1920 (31.0)    7072 (31.1)
  Northeast                     6367 (22.0)    537 (18.5)    2013 (19.5)      667 (20.3)      3150 (25.4)   1204 (19.4)    5163 (22.7)
  Northwest                     4824 (16.7)    301 (10.4)    1984 (19.2)      321 (9.8)       2218 (17.9)   622 (10.0)     4202 (18.5)

Abbreviations: ILI, influenza-like illness; IQR, interquartile range; LAIV, live, attenuated influenza vaccine; TIV, trivalent inactivated influenza vaccine.

Numbers (percentages) for all data except age, which is reported as median (IQR).

Women, officers, those with a potential alcohol problem, those serving in the Navy or Marine Corps (vs Army or Air Force), those residing in the US Southwest (vs each other region) and in a health care occupation (vs combat or other occupation) were less likely than comparison groups to have received LAIV (p\<0.0001). Additionally, compared with 2006/2007, those vaccinated in 2008/2009 were more likely to have received LAIV (p = 0.04). Vaccine type did not significantly differ by age, smoking status, exercise level, marital status, or race/ethnicity.

During the 2 seasons, 3936 ILI events were diagnosed, for an overall crude ILI incidence rate of 136.1 cases per 1000 person-seasons. Weekly ILI case volume demonstrated a pattern similar to that of positive influenza isolates in the general population reported by CDC over the same time period [@pone.0102154-Centers1], [@pone.0102154-Centers3]. ILI rates for LAIV and TIV were 138.5 and 127.0 cases per 1000 person-seasons, respectively. The ILI rate by vaccine type did not significantly vary by season.

In the univariable model, type of vaccine was not associated with the development of ILI (HR, 1.02; 95% CI, 0.95--1.11) ([Table 3](#pone-0102154-t003){ref-type="table"}). Factors associated with an increased risk of ILI included recent smoking history, younger age, female sex, other race/ethnicity, and health care occupation. Those serving in the Army or Marine Corps (compared with the Air Force), officers, and combat specialists had a lower risk ([Table 3](#pone-0102154-t003){ref-type="table"}).

10.1371/journal.pone.0102154.t003

###### Univariable Hazard Risk Ratios for ILI Among US Service Members, 18--49 Years of Age, During 2006/2007 and 2008/2009 Influenza Seasons.
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  Characteristic               ILI Events   
  --------------------------- ------------- ---------------------------------------------------
  Vaccine type                              
  TIV                          787 (12.7)                       1.00 (Ref)
  LAIV                         3149 (13.9)                   1.02 (0.95--1.11)
  Recent smoking history                    
  Yes                          1123 (14.1)   1.09 (1.02--1.17)[a](#nt104){ref-type="table-fn"}
  No                           2813 (13.4)                      1.00 (Ref)
  Potential alcohol problem                 
  Yes                          267 (12.0)                    0.90 (0.79--1.02)
  No                           3669 (13.7)                      1.00 (Ref)
  Exercise level                            
  Minimal                      439 (14.4)                    1.05 (0.94--1.16)
  Moderate                     2782 (13.7)                      1.00 (Ref)
  High                         133 (10.4)                    0.79 (0.66--0.95)
  Unknown                      582 (13.7)                    1.00 (0.91--1.09)
  Age, y                                     0.99 (0.98--0.99)[a](#nt104){ref-type="table-fn"}
  Sex                                       
  Male                         2339 (11.1)                      1.00 (Ref)
  Female                       1597 (20.1)   1.84 (1.72--1.96)[a](#nt104){ref-type="table-fn"}
  Race/ethnicity                            
  White                        2823 (13.4)                      1.00 (Ref)
  Black                        486 (13.4)                    1.00 (0.91--1.10)
  Hispanic                     290 (14.0)                    1.08 (0.95--1.22)
  Other/unknown                337 (15.7)    1.17 (1.04--1.32)[a](#nt104){ref-type="table-fn"}
  Marital status                            
  Married                      2420 (13.6)                      1.00 (Ref)
  Other                        1516 (13.7)                   1.02 (0.96--1.09)
  Service branch                            
  Air Force                    2363 (16.5)                      1.00 (Ref)
  Army                         1047 (11.1)   0.74 (0.68--0.79)[a](#nt104){ref-type="table-fn"}
  Marine Corps                  197 (6.6)    0.43 (0.37--0.50)[a](#nt104){ref-type="table-fn"}
  Navy                         329 (14.6)                    0.90 (0.80--1.02)
  Military rank                             
  Enlisted                     3140 (14.3)                      1.00 (Ref)
  Officer                      796 (11.4)    0.77 (0.71--0.84)[a](#nt104){ref-type="table-fn"}
  Occupation                                
  Combat                       531 (10.2)    0.76 (0.69--0.84)[a](#nt104){ref-type="table-fn"}
  Health care                  783 (18.3)    1.28 (1.18--1.39)[a](#nt104){ref-type="table-fn"}
  Other                        2622 (13.5)                      1.00 (Ref)
  US geographic area                        
  Southwest                    1203 (13.8)                      1.00 (Ref)
  Southeast                    1192 (13.3)                   0.98 (0.90--1.06)
  Northeast                    832 (13.1)                    0.92 (0.84--1.00)
  Northwest                    709 (14.7)                    1.04 (0.95--1.15)
  Influenza season                          
  2006--2007                   1860 (14.1)                      1.00 (Ref)
  2008--2009                   2076 (13.2)   1.07 (1.00--1.14)[a](#nt104){ref-type="table-fn"}

Abbreviations: CI, confidence interval; HR, hazard ratio; ILI, influenza-like illness; LAIV, live, attenuated influenza vaccine; TIV, trivalent inactivated influenza vaccine.

*p*\<0.05.

In the final multivariate model, adjusted for all significant covariates and using average values for health behaviors in vaccine type interaction terms, the risk of ILI did not significantly differ between LAIV and TIV (HR, 0.98; 95% CI, 0.90--1.06) ([Table 4](#pone-0102154-t004){ref-type="table"}). In the final adjusted model, the relative effectiveness of the 2 vaccine types did not differ by smoking status (*p* = 0.10), alcohol status (*p* = 0.21), or activity level (*p* = 0.11). In addition, ILI risk did not significantly differ by vaccine type among smokers (n = 7955) (HR, 1.09; 95% CI, 0.94--1.27), nonsmokers (n = 20,974) (HR, 0.94; 95% CI, 0.85--1.03), those with a potential alcohol problem (n = 2221) (HR, 1.19; 95% CI, 0.86--1.63), those without an alcohol problem (n = 26,708) (HR, 0.96; 95% CI, 0.89--1.05), those reporting a high exercise level (n = 1283) (HR, 1.12; 95% CI, 0.71--1.76), and those reporting a minimal exercise level (n = 3039) (HR, 1.08; 95% CI, 0.85--1.36) in the model adjusting for sociodemographic factors and the other adverse health behaviors of interest. Similar findings resulted from examining health behaviors by vaccine type for each season separately.

10.1371/journal.pone.0102154.t004

###### Risk of ILI by Vaccine Type and Health Behavior During Two Influenza Seasons (2006/2007, 2008/2009).
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                                                        Vaccine Type                                              
  --------------------------- -------- ------- ------- -------------- ------ ------- ------ ----- ------- ------- -------------------
  Overall                      28,929   3936    13.61      22,734      3149   13.85   6195   787   12.70           0.98 (0.90--1.06)
  Recent smoking history                                                                                   0.099  
  Nonsmoker                    20,974   2813    13.41      16,496      2228   13.51   4478   585   13.06           0.94 (0.85--1.03)
  Smoking history               7955    1,123   14.12       6238       921    14.76   1717   202   11.76           1.09 (0.94--1.27)
  Possible alcohol problems                                                                                0.209  
  No drinking problem          26,708   3669    13.74      21,079      2933   13.91   5629   736   13.08           0.96 (0.89--1.05)
  Possible drinking problem     2221     267    12.02       1655       216    13.05   566    51    9.01            1.19 (0.86--1.63)
  Exercise level                                                                                           0.114  
  Moderate                     20,345   2782    13.67      16,032      2209   13.78   4313   573   13.29           0.92 (0.84--1.01)
  Minimal                       3039     439    14.45       2334       348    14.91   705    91    12.91           1.08 (0.85--1.36)
  High                          1283     133    10.37       1007       108    10.72   276    25    9.06            1.12 (0.71--1.76)
  Unknown                       4262     582    13.66       3361       484    14.40   901    98    10.88           1.19 (0.96--1.48)

Abbreviations: CI, confidence interval; HR, hazard ratio; ILI, influenza-like illness; LAIV, live, attenuated influenza vaccine; TIV, trivalent inactivated influenza vaccine.

Hazard ratio for each health behavior stratum is evaluated at the average level of other behaviors in the study population and adjusted for all other demographic covariates.

Discussion {#s4}
==========

This study demonstrated that the relative effectiveness of LAIV versus TIV in preventing ILI among young adults did not vary by health-related behaviors (tobacco, alcohol use, or exercise level) using data from the 2006/2007 and 2008/2009 influenza seasons. These findings are in accordance with current recommendations regarding influenza vaccine from the Advisory Committee on Immunization Practices [@pone.0102154-Centers6] and indicate that tailoring vaccine type recommendations to these specific health behavior groups is not warranted.

The effectiveness of the influenza vaccine depends on the recipient\'s immunocompetence, the similarity of vaccine strains to circulating strains in a population (ie, the "match"), the outcome measured, and possibly the mode of vaccine delivery. The role of immunocompetence, since it may be modulated by particular health behaviors, and its interaction with the mode of vaccine delivery were explored by controlling for both the vaccine match (by selecting 2 well-matched seasons) and the outcome measured (ILI). Several health behaviors that may have differential effects on vaccine effectiveness against influenza-related events were examined.

Tobacco and alcohol misuse have been associated with a higher risk for influenza and related complications [@pone.0102154-Meyerholz1], [@pone.0102154-Arcavi1], hence data on the optimal vaccine type in this group are important for patient care and public health strategies. Tobacco use is known to result in respiratory tract (impaired ciliary action) and immune (altered humoral and cell-mediated immunity) dysfunction from exposure to carcinogens, toxins, and lipopolysaccharide [@pone.0102154-Edwards1]. Further, a tobacco dose-related decrease in salivary IgA levels among smokers, a decrease in serum IgG, and alterations in immune cell counts (including lymphocytes, monocytes, B cells, and helper and suppressor T cells) have been described [@pone.0102154-Edwards1]. Hence, impaired mucosal immunity among smokers offers a biologically plausible reason for smokers to respond differently to LAIV (administered to the nasal mucosa) compared with TIV. Prior to this study, a single study had found a significant interaction between cigarette smoking and influenza vaccination by circulating influenza antibodies [@pone.0102154-Cruijff1], however, no difference in protection against clinical influenza was found. Overall, these data and the current study findings do not support a differential response by vaccine type among smokers and nonsmokers.

Regarding excessive alcohol use, resultant negative cellular and innate immune system effects, including weakened antiviral defense mechanisms, have been described [@pone.0102154-Cook1]--[@pone.0102154-Szabo2], [@pone.0102154-Pavia1]--[@pone.0102154-Lau1]. The antigen-presenting function of innate immune cells (eg, monocytes and macrophages) may be inhibited by alcohol exposure, and both T-cell proliferation and the distribution and functions of memory T cells and natural killer cells altered. Despite these potential immunologic changes, we did not find a differential response by vaccine type among problem drinkers.

Transient immunosuppression has been documented following intense and/or prolonged physical activity, though baseline disease rates have not been shown to differ between athletes and nonathletes [@pone.0102154-Nieman1]--[@pone.0102154-Mackinnon1], and athletes typically report decreased rates of infection on surveys [@pone.0102154-Nieman1]. Specific immune system effects of exercise such as low salivary IgA associated with intense exercise in elite athletes have been documented and may vary according to an individual\'s conditioning [@pone.0102154-Gleeson1], [@pone.0102154-Mackinnon1]. However, studies have found that 2--4 weeks after prolonged intensive exercise, individuals mount a normal antibody response to vaccination (tetanus, diphtheria, pneumococcus) [@pone.0102154-Bruunsgaard1]--[@pone.0102154-Eskola1]. It seems plausible that altered immunity could also appear with a sedentary lifestyle. Boosting of immunity and reduction in the number of days reporting upper respiratory symptoms among those engaging in exercise compared with sedentary controls have been described [@pone.0102154-Nieman1], [@pone.0102154-Venjatraman1]. Although, a difference in efficacy conferred by LAIV compared with TIV might be hypothesized among groups with minimal or high exercise levels, we found no differences in ILI by vaccine type.

Overall, no difference in risk of ILI between LAIV and TIV recipients by each of the health behaviors of interest was found, likely reflecting the lack of effect on vaccine responses. It is also possible that the behavior categorization did not adequately separate those more likely to experience immune system effects due to their behavior from those at low risk of such effects; however, the military does contain sufficient numbers of persons with varying health behaviors, and the evaluation of more extreme behaviors may be less generalizable to the overall population.

One methodological limitation of this study is that the outcomes measured were based on ICD-9 codes rather than laboratory-confirmed influenza diagnosis; however, the codes used have been previously shown to correlate with viral culture or polymerase chain reaction-confirmed influenza events [@pone.0102154-Eick1], [@pone.0102154-MarsdenHaug1], [@pone.0102154-Wang1]. Also, illnesses that did not result in a health care visit within the military system could not be captured. Health behavior data were self-reported on a questionnaire and may not reflect the actual behaviors at the time of vaccine receipt. Since this study examined the potential associations between exposures and the effectiveness of the different vaccine types, by design it was only able to evaluate the apparent relative effectiveness of each vaccine. Lastly, this study included only a subset of adults serving in the US military; hence, data may not be representative of the entire military population. Further, although service members reflect a fairly broad spectrum of socioeconomic status and geographic distribution, additional research may be warranted to examine differential vaccine type effects on influenza outcomes among civilian groups with other health behavior profiles.

To the authors\' knowledge, this is the first study to examine the effects of particular health behaviors on the relationship between vaccine type and influenza outcome. Strengths of this study include its robust size with nearly 30,000 vaccination events evaluated. In addition, the study utilized self-reported health behavior data proximate to vaccine receipt in a large population with reliable health care encounter capture. Further, military vaccine records used were comprehensive and highly reliable. Finally, the ILI rate (13.6%, n\>3,000) allowed for robust measurement of the effects of health behavior factors.

In summary, LAIV and TIV have similar effectiveness in preventing ILI events among healthy 18- to 49-year-olds who are smokers, have potential alcohol problems, or endorse minimal or high exercise levels. These data suggest that clinicians and public health practitioners need not tailor vaccine regimens according to the particular health behavior groups studied here, and instead should focus vaccination efforts on simply ensuring widespread vaccination.
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